Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
GlaxoSmithKline plc
Index- P/E6.83 EPS (ttm)6.53 Insider Own- Shs Outstand2.47B Perf Week-0.16%
Market Cap110.00B Forward P/E16.90 EPS next Y2.64 Insider Trans- Shs Float2.39B Perf Month-3.55%
Income15.76B PEG0.89 EPS next Q- Inst Own10.10% Short Float0.22% Perf Quarter-5.31%
Sales35.65B P/S3.09 EPS this Y-48.80% Inst Trans0.50% Short Ratio1.46 Perf Half Y-1.18%
Book/sh4.77 P/B9.35 EPS next Y0.96% ROA22.90% Target Price45.67 Perf Year-14.29%
Cash/sh6.49 P/C6.87 EPS next 5Y7.70% ROE178.10% 52W Range40.13 - 52.36 Perf YTD7.29%
Dividend2.31 P/FCF- EPS past 5Y-12.20% ROI15.00% 52W High-14.80% Beta0.58
Dividend %5.18% Quick Ratio1.00 Sales past 5Y-4.10% Gross Margin68.70% 52W Low11.16% ATR0.72
Employees98702 Current Ratio1.30 Sales Q/Q0.20% Oper. Margin21.50% RSI (14)45.37 Volatility1.11% 1.13%
OptionableYes Debt/Eq2.48 EPS Q/Q1110.90% Profit Margin44.10% Rel Volume0.84 Prev Close43.84
ShortableYes LT Debt/Eq2.05 EarningsMay 06 Payout37.90% Avg Volume3.52M Price44.61
Recom2.80 SMA20-0.99% SMA50-3.19% SMA200-0.16% Volume2,956,936 Change1.76%
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-16-10Upgrade JP Morgan Underweight → Neutral $26
Jan-13-10Downgrade Credit Suisse Outperform → Underperform
Nov-24-09Initiated Leerink Swann Mkt Perform
Nov-16-09Initiated Deutsche Securities Hold
Nov-12-09Initiated Barclays Capital Equal Weight
Oct-23-09Downgrade Jefferies & Co Buy → Hold
Mar-17-09Initiated Credit Suisse Outperform
Jan-26-09Initiated Jefferies & Co Buy
Nov-14-08Downgrade UBS Buy → Neutral
Apr-18-08Downgrade JP Morgan Neutral → Underweight
Feb-11-08Upgrade UBS Neutral → Buy
Feb-01-08Upgrade HSBC Securities Underweight → Neutral
May-26-15 09:00AM  ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV PR Newswire
May-24-15 07:19PM  Innovation and scale fuel growth in Big Pharma at Financial Times
06:21PM  Investors prepared to give Sir Andrew Witty time to revive GSK at Financial Times
May-22-15 07:58PM  Would Pfizer Buying GlaxoSmithKline Make Sense? at Investopedia
08:11AM  Who are Gilead Sciences' (GILD) main competitors? at Investopedia
May-21-15 05:35PM  All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A at Bloomberg
12:45PM  How a "PfizerKline" would impact the Triangle at
May-20-15 05:25PM  $5.6B In Fines Against Major Banks Seems Like A Lot. Here's Why It Won't Deter Corporate Crime. at Forbes
01:50PM  GSK unmoved by broker talk of takeover at Financial Times
08:54AM  Pfizer Would Benefit From Glaxo Takeover, Deutsche Bank Says at Bloomberg
May-19-15 09:00AM  New Study Shows Inner-City Asthma Care Program Reduces Student Absenteeism by up to 20 Percent PR Newswire
May-15-15 06:00PM  Cramer: Next week jam-packed with retail earnings
04:21PM  Healthcare Winners and Losers: May 15, 2015
May-14-15 04:55PM  Emergent BioSolutions, Glaxo Initiate Ebola Vaccine Study - Analyst Blog
12:57PM  FTSE 100 finds its footing as Draghi backs eurozone stimulus at MarketWatch
07:13AM  Is Sir Andrew Witty The Person To Lead A Major Pharmaceutical Company? at Forbes
May-12-15 08:31AM  GSK's Curious Oncology Research Position -- A Recipe For Failure? at Forbes
May-11-15 02:34PM  CNBC update: Ukraine warning
01:14PM  GlaxoSmithKline chief questions rivals' chasing M&A deals at Financial Times
01:13PM  GlaxoSmithKline: Out of step at Financial Times
01:03PM  HIV Cure Is Goal of Glaxo-UNC Chapel Hill Partnership at The Wall Street Journal
May-10-15 10:06PM  Partnership Takes Aim at Curing HIV/AIDS at The Wall Street Journal
10:00PM  Hunt for AIDS cure accelerates as GSK and U.S. experts link up
11:31AM  GlaxoSmithKline chief seeks immunity from sector's herd mentality at Financial Times
May-08-15 12:47PM  Week in Review, May 9 at Financial Times
May-07-15 03:10PM  Glaxo's (GSK) Q1 Earnings Fall Y/Y; Gives Five-Year View - Analyst Blog
12:45PM  Outgoing chairman defends record at GSK at Financial Times
11:50AM  Theravance (THRX) Reports Wider-than-Expected Q1 Loss - Analyst Blog
11:48AM  New GSK chairman backs CEO Witty to stay at helm
08:07AM  GlaxoSmithKline plc announces Board and Committee changes at noodls
03:50AM  U.K. Stocks Fall as Voting Begins, With GlaxoSmithKline Dropping at Bloomberg
May-06-15 10:25PM  China Said to Probe Ex-Official Who Oversaw Clinical Drug Trials at Bloomberg
07:54PM  PRESS DIGEST- British Business - May 7 Reuters
07:03PM  United Kingdom votes in most unpredictable election in decades Reuters
06:08PM  Today's Top 5 Stock Picks: Undervalued Large-Caps at
04:41PM  Drug developer Adaptimmune skids after IPO raises $191M
01:33PM  GSK's Sturdy Strategy Leaves Investors Waiting at The Wall Street Journal
01:17PM  GSK's new strategy
12:53PM  GlaxoSmithKline Won't Sell Its HIV Drugs Unit, Cuts Shareholder Payout at TheStreet
12:49PM  Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong at Investor's Business Daily
12:33PM  GSK Cuts Return to Shareholders From Novartis Deal at The Wall Street Journal
12:32PM  GSK sees little prospect of U.S. generic Advair in 2016
12:13PM  GSK: Hard choice at Financial Times
11:48AM  Glaxo Starts Singing Different Tune on Threat of Generic Advair at Bloomberg
11:40AM  Drug developer Adaptimmune wavers after IPO raises $191M
11:10AM  PAREXEL Q3 Earnings in Line; FY15 Top-line View Trimmed - Analyst Blog
10:55AM  Stocks off lows amid higher yields, Yellen remarks on valuation at CNBC
10:23AM  GlaxoSmithKline opts to hold on to HIV business
10:06AM  GSK scraps plan to list HIV drugs business and shields dividend
09:40AM  Glaxo Abandons HIV-Unit Spinoff Plan, Reduces Capital Payout
08:42AM  Glaxo (GSK) Misses on Q1 Earnings, Gives 5-Year Outlook - Tale of the Tape
08:15AM  GSK drops plans for IPO of HIV drugs unit at Financial Times
07:51AM  Early movers: GEVA, MGI, JPM, WEN, NWSA & more at CNBC
07:49AM  GSK, Fondazione Telethon and Ospedale San Raffaele announce EU regulatory submission for gene therapy to treat rare disease ADA-SCID at noodls
07:22AM  GSK rules out HIV spinout as generics hit results at CNBC
07:20AM  Glaxo Cuts Payment to Investors as Earnings Miss Estimates at Bloomberg
04:51AM  ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy PR Newswire
May-05-15 09:06PM  Why Novartiss Operating Margins Expanded in 1Q15
12:45PM  Winners and Losers: Healthcare May 01, 2015
09:30AM  LyondellBasell, Container Store, GlaxoSmithKline, Novartis and Genocea Biosciences highlighted as Zacks Bull and Bear of the Day - Press Releases
09:19AM  Transparency Is Still A Problem As Big Pharma Struggles With Its Image at Forbes
08:57AM  Why Earnings Season Could Be Great for GlaxoSmithKline (GSK) - Tale of the Tape
05:28AM  Prescription for Glaxo: A New Boss?
12:01AM  Prescription for Glaxo: A New Boss? at Bloomberg
May-04-15 05:10PM  Will Glaxo (GSK) Beat Earnings Estimates This Season? - Analyst Blog
12:28PM  Corporate diary: May 4 - May 8 at Financial Times
11:48AM  China Investigating Siemens' Business Practices at The Wall Street Journal
May-01-15 09:22AM  British Stock Markets Volatile over May 7 UK Elections
09:17AM  5 Toxic Stocks to Sell in May at TheStreet
07:03AM  Doubts grow over GlaxoSmithKline's $6 bln capital return plan
Apr-30-15 06:09PM  Six Takeaways from Gilead's Conference Call at
05:31PM  U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug Reuters
05:05PM  GSK wins approval for asthma drug; will be produced in Zebulon at
04:36PM  FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US PR Newswire
03:48PM  Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma
03:46PM  Glaxo gets OK to expand marketing of inhaler drug
Apr-29-15 12:00PM  Intellectual Property Rights For Global Health at Forbes
10:54AM  Q1 Growth Falls Short as UK Elections Draw Near, Yet EWU Up 0.44%
Apr-28-15 12:35PM  Pfizer Rumored To Be Eyeing British Giant GlaxoSmithKline
12:27PM  GSK reveals strong trial results for shingles drug at Financial Times
11:31AM  CNBC update: 12 killed in Brazilian landslide
06:38AM  GSK shingles vaccine shows benefits across all age groups
Apr-27-15 02:05PM  Bulls come back to GlaxoSmithKline
10:04AM  GSK readies "bubble boy" drug as big pharma bets on gene therapy Reuters
Apr-24-15 02:30PM  CNBC update: First malaria vaccine could be approved
02:11PM  Valeant Pharmaceuticals Intl Inc (VRX), Apple Inc. (AAPL), McDonalds Corporation (MCD): A Look At Locust Woods Major First Quarter Moves at Insider Monkey
10:00AM  Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog
05:30AM  Problems Found With Glaxo's Malaria Vaccine at The Wall Street Journal
Apr-23-15 11:06PM  VGK and EFA up on Good Inflation News from Germany and France
06:21PM  Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog
03:06AM  AQR Capital More Than Doubles its Holdings in Gilead Sciences
03:05AM  Novartis (NVS) Beats on Earnings & Revenues - Tale of the Tape
02:58AM  Divestment gains boost net earnings at drug company Novartis
01:57AM  Novartis Profit Boosted Disposals at The Wall Street Journal
Apr-22-15 09:49PM  Novartis keeps full-year target as Q1 earnings fall AFP
01:25PM  Tate & Lyle slides as analyst turns negative at Financial Times
Apr-21-15 02:50PM  Will Novartis' (NVS) Earnings Disappoint This Quarter? - Analyst Blog
Apr-20-15 03:02PM  BioMed Realty, L.P. -- Moody's upgrades BioMed's senior unsecured ratings to Baa2; outlook is stable at Moody's
Apr-17-15 07:44PM  Veeva's Latest Solution to Ease Medical Product Rollouts - Analyst Blog
06:40PM  Pfizer Wins First Trial Over Zoloft Birth-Defect Claims
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company's wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company's nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerMay 11Buy14.00365,1065,111,484365,106May 13 12:36 PM
GLAXOSMITHKLINE PLC10% OwnerMar 02Buy18.0692,6741,673,69231,673,853Mar 02 03:45 PM
GLAXOSMITHKLINE PLC10% OwnerAug 11Buy22.66172,6513,912,27230,748,723Aug 11 04:55 PM